Since working up Seattle Genetics in the year 1998, he has driven the firm to the summit of the focused on treatment industry. Building up the key FDA-grasped immunizer calm conjugate, which now has different confirmed signs, and moreover building up a robust pipeline of more than 20 drugs and a string of primary relationship with pharmaceutical makers including Bayer, Genentech, Pfizer and different others.
Under Dr. Siegall’s drive, Seattle Genetics has gone from a minor startup with only a skeleton social affair of inspectors to a real power player in the risk examine space. Furthermore, Dr. Clay Siegall has titanic game-plans for the affiliation’s future. With a never-ending creating rundown of drugs in the change pipeline and a determinedly developing number of potential signs for the affiliation’s balanced movement medicine portfolio, Seattle Genetics is mainly organized to move into the 21st-century steady progress industry with an expert.
Dr. Siegall expects that the old secure of tumor treatment, to be specific, systemic chemotherapies, are bound for the huge dustbin. As the respect and adequacy of focused solutions push toward getting the chance to be clearer in the decades to come, Dr. Siegall accept that the meds of old will be supplanted by the significantly more passable and unfathomably more compelling focused on medicines.
Dr. Siegall helped to establish Seattle Genetics in 1998 and is the organization’s President, Chief Executive Officer and Chairman of the Board of Directors. Under his authority, Seattle Genetics has constructed a different pipeline of counteracting agent based disease treatments, including ADCETRIS (brentuximab vedotin) that was conceded quickened endorsement by the U.S. Nourishment and Drug Administration (FDA) in 2011.
Dr. Siegall has additionally guided Seattle Genetics/capital-raising exercises, securing more than $675 million through open and private financings, including the organization’s first sale of stock in 2001. Preceding helping to establish Seattle Genetics, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute from the year 1991 to 1997 and the National Cancer Institute, National Institutes of Health from the year 1988 to 1991. He works on a private biotechnology organization and the Board of Directors of Alder BioPharmaceuticals. Dr. Siegall is a creator on an extent of 70 distributions and holds 15 licenses. He got a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.